From GlobeNewswire:

Biodexa Pharmaceuticals PLC has announced the closing of a $6.0 million public offering, with the full exercise of the over-allotment option. The company also acquired an exclusive, worldwide license to Tolimidone, a Phase II Ready Type I Diabetes clinical program. Tolimidone is a selective activator of the enzyme lyn kinase, discovered by Pfizer and tested in over 700 patients. The offering includes the sale of Class A and Class B units, consisting of Depositary Shares and Warrants. Biodexa’s lead candidate, MTX110, is being studied for primary and metastatic brain cancers, with a focus on improving drug delivery technologies.



Read more at GlobeNewswire: Biodexa Announces Closing Of $6.0 Million Underwritten